Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

NCT01887587 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped SAE- risk of overall protocol treatment outweighs benefits

Conditions

Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Lymphoblastic Lymphoma
Mixed Phenotype Acute Leukemia

Interventions

DRUG: MLN9708
DRUG: Vincristine
DRUG: Doxorubicin
DRUG: Dexamethasone

Sponsor

Ehab L Atallah